In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out.Â
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.